AI Research
AI Binders Worked on One of Three Cancer Targets
The failure mode is the finding: designs that bound perfectly still broke as CAR receptors, defeated by a property outside the interface the AI optimised.
Aug 21, 2026
#oncology
Healthcare AI
Tempus AI to Buy Cancer-Test Maker Personalis for $1.7 Billion, Betting on MRD Detection
The AI precision-oncology platform is folding tumor-informed molecular residual disease testing into its stack, chasing a US market it sizes at more than $20 billion.
Jul 21, 2026
